argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG technology
October 08, 2018 at 21:00 PM EDT
October 9, 2018
The €2.6 million subsidy from VLAIO was granted to argenx through its Innovative Access Program (IAP) to fund new research around the proprietary ABDEG™ technology. argenx believes the IAP creates a foundation to build upon its unique and sustainable pipeline while providing access for its cutting edge antibody discovery technologies to centers of novel target research.
About SIMPLE AntibodyTM Platform
About the Innovative Access Program
For further information, please contact:
Beth DelGiacco, VP Investor Relations (US)